Organon (OGN) CMO receives 200,333 RSUs and exercises prior award

Rhea-AI Filing Summary

Organon & Co. Head of R&D & CMO Juan Camilo Arjona Ferreira reported equity compensation and related share movements. On March 31, 2026, he received a grant of 200,333 Restricted Stock Units (RSUs), each representing one share of Organon common stock, vesting in three equal installments on March 31, 2027, 2028, and 2029.

On the same date, he exercised 13,431 RSUs from a prior March 31, 2025 grant, receiving an equal number of common shares. Of these, 4,820 shares of common stock were withheld at $5.70 per share to cover tax obligations. Following these transactions, he directly holds 30,047.477 shares of common stock and 200,333 RSUs.

Insider Trade Summary

13,431 shares exercised/converted

Mixed 4 txns

Insider Arjona Ferreira Juan Camilo

Role Head of R&D & CMO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	200,333	$0.00	--
Exercise	Restricted Stock Units	13,431	$0.00	--
Exercise	Common Stock	13,431	$0.00	--
Tax Withholding	Common Stock	4,820	$5.70	$27K

Holdings After Transaction: Restricted Stock Units — 200,333 shares (Direct); Common Stock — 34,867.477 shares (Direct)

Footnotes (1)

1. The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Each RSU represents a contingent right to receive one share of Organon common stock. On March 31, 2025, the Reporting Person was granted 40,295 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Key Figures

New RSU grant: 200,333 RSUs RSUs exercised: 13,431 RSUs Shares withheld for taxes: 4,820 shares at $5.70 +2 more

5 metrics

New RSU grant 200,333 RSUs Granted March 31, 2026; each RSU equals one common share

RSUs exercised 13,431 RSUs Exercised March 31, 2026 from March 31, 2025 grant

Shares withheld for taxes 4,820 shares at $5.70 Common stock withheld March 31, 2026 to cover tax liability

Common shares after transactions 30,047.477 shares Direct common stock holdings following March 31, 2026 transactions

2025 RSU grant size 40,295 RSUs Granted March 31, 2025; vests in thirds in 2026, 2027, 2028

Key Terms

Restricted Stock Units, contingent right, tax liability, closing market price, +1 more

5 terms

Restricted Stock Units financial

"the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

contingent right financial

"Each RSU represents a contingent right to receive one share of Organon common stock"

tax liability financial

"Payment of exercise price or tax liability by delivering securities"

closing market price financial

"The price is the closing market price of Organon & Co. common stock"

vest financial

"These RSUs will vest and become exercisable in three equal installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Arjona Ferreira Juan Camilo

(Last) (First) (Middle)

C/O ORGANON &CO.

30 HUDSON STREET, FLOOR 33

(Street)

JERSEY CITY NEW JERSEY 07302

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of R&D & CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/31/2026		M		13,431	A	$0	34,867.477	D
Common Stock	03/31/2026		F		4,820	D	$5.7(1)	30,047.477	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(2)	03/31/2026		A		200,333		(2)	(2)	Common Stock	200,333	$0	200,333	D
Restricted Stock Units	(3)	03/31/2026		M			13,431	(4)	(4)	Common Stock	13,431	$0	26,864	D

Explanation of Responses:

1. The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded.

2. On March 31, 2026, the Reporting Person was granted 200,333 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029.

3. Each RSU represents a contingent right to receive one share of Organon common stock.

4. On March 31, 2025, the Reporting Person was granted 40,295 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028.

Remarks:

	/s/ Tarnetta Jones, as Attorney-in-fact for Dr. Juan Camilo Arjona Ferreira	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did Organon (OGN) grant to Juan Camilo Arjona Ferreira?

Organon granted Juan Camilo Arjona Ferreira 200,333 Restricted Stock Units (RSUs) on March 31, 2026. Each RSU represents a contingent right to receive one share of Organon common stock, vesting in three equal installments in 2027, 2028, and 2029.

How and when will the new RSUs for Organon (OGN) vest?

The 200,333 RSUs granted on March 31, 2026 will vest in three equal installments. They become exercisable on March 31, 2027, March 31, 2028, and March 31, 2029, with each vested unit delivering one share of Organon common stock.

What RSU grant from 2025 did the Organon (OGN) executive exercise?

On March 31, 2026, the executive exercised 13,431 RSUs from a 40,295 RSU grant originally awarded on March 31, 2025. One-third vested on March 31, 2026, with the remaining two-thirds scheduled to vest on March 31, 2027 and March 31, 2028.

How many Organon (OGN) shares were withheld for taxes in this Form 4?

A total of 4,820 shares of Organon common stock were withheld on March 31, 2026 to satisfy tax obligations. These shares were valued at $5.70 per share, reflecting payment of exercise price or tax liability by delivering securities.

What are the Organon (OGN) share holdings of the executive after these transactions?

After the reported transactions, the executive directly holds 30,047.477 shares of Organon common stock. He also holds 200,333 RSUs that each represent a contingent right to receive one share upon future vesting and settlement dates.

What role does Juan Camilo Arjona Ferreira hold at Organon (OGN)?

Juan Camilo Arjona Ferreira is identified as an officer of Organon & Co., serving as Head of R&D & Chief Medical Officer (CMO). The reported RSU grants and share movements are part of his equity-based compensation.